WebMD -- Recent data suggesting the cholesterol-lowering drug Vytorin ups cancer risk can’t yet be dismissed, the editor of The New England Journal of Medicine says. The worrisome cancer data come from a clinical trial called SEAS, reported today at a major European cardiology conference and simultaneously published online by The New England Journal of Medicine. But these findings come as no surprise.
